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um marker. Because of this conditional relationship, ser-
um marker performance should at best approach
accuracy of liver biopsy. Therefore, it is rather surpris-
ing to support serum markers, arguing on biopsy weak-
ness when this tool is chosen to deﬁne the formula of
serum markers. Finally, Poynard et al. suggest that
screening for advanced ﬁbrosis is a public health chal-
lenge and this can only be achieved through a morato-
rium of liver biopsy as a ﬁrst-line estimate. Anybody
would agree that screening of advanced ﬁbrosis does
not rely on liver biopsy and that non-invasive tests have
excellent accuracy in this setting but there is a major dif-
ference between screening for advanced ﬁbrosis and
staging ﬁbrosis. Non-invasive tests have shown decep-
tively low performance in this matter with signiﬁcant
overlap between adjacent stages.
The risk of performing a liver biopsy should always
be discussed with regards to the potential beneﬁt for
the patient and in this context any dogmatic statement,
either in favour or against it, is dangerous. Today, anti-
viral therapy has still limited eﬃcacy and is associated
with serious adverse eﬀects. Therefore management of
patients using only a screening procedure for advanced
ﬁbrosis, such as serum markers, will clearly lead to an
obvious loss of opportunities for patients to be
adequately and timely treated, a risk that surpasses the
adverse events of the biopsy.
Therefore, in the present situation, non-invasive ser-
um markers are eﬃcient screening instruments for
advanced ﬁbrosis or cirrhosis but remain a dead endwhen addressing the accurate evaluation of liver
damage.
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doi:10.1016/j.jhep.2009.02.011Pioglitazone as adjuvant therapy in chronic hepatitis C: Sequential
rather than concomitant administration with pegylated interferon
and ribavirin?To the Editor:
We read with interest the article by Overbeck
et al., published in the August issue of the Journal of
Hepatology [1]. This study investigating pioglitazone as
adjuvant therapy in hepatitis C patients not responding
to pegylated interferon and ribavirin was terminated be-
cause no eﬀect on viral load was observed, despite a de-
crease of the homeostasis model assessment (HOMA)
index in some patients. We believe that there were sev-
eral inadequacies in the study design that may be at
the origin of the negative results. First, the dosage of
pioglitazone (15 mg) was rather low. Second, because
of the delayed eﬀect of pioglitazone on insulin resistance
and steatosis, starting its administration concomitantly
with the antiviral therapy may be untimely [2].Here, we report the eﬀect of a sequential adminis-
tration of pioglitazone at higher dosage upon retreat-
ment of a patient with chronic hepatitis C and
steatosis who had not responded to a prior regimen
of pegylated interferon and ribavirin. A 43-year-old
man with chronic HCV infection was admitted to
our Department at Saint-Antoine Hospital in Novem-
ber 2004 for liver biopsy. Known risk factor was IV
drug use between 1982 and 1990. The patient had
no previous history of diabetes, dylipidemia or hyper-
tension. Alcohol consumption was discontinued 6
months earlier. Chronic HCV infection was diagnosed
in April 2004 based on positive anti-HCV antibodies
(ELISA) and detectable HCV RNA by RT-PCR
(Amplicor HCV, Roche). At this time, ALT, AST
and GGT activities were 3.5  N, 1.4  N and
2.5  N, respectively. At admittance, physical exami-
nation showed normal blood pressure and no over-
weight, the body mass index being 23.5 kg/m2.
Biochemistry revealed ALT activity 2.5  N, AST
1.2  N and GGT 2.5  N. Prothrombin time, biliru-
binemia, albuminemia and hemogram were in normal
range. Fasting serum glucose, triglyceride, total and
HDL cholesterol levels were in the normal range.
Virological assays showed genotype 3 infection and
serum HCV RNA at 215,123 IU/ ml (Bayer VER-
SANT HCV RNA 3.0, lower limit of detection
615 IU/ml). Other causes of chronic liver disease were
excluded with appropriate tests (HBV or HIV infec-
tions, genetic hemochromatosis, Wilson disease and
autoimmune liver diseases). Liver US showed bright li-
ver. Liver biopsy of adequate (25 mm) size showed
chronic hepatitis with METAVIR score A2F3 and
macrovacuolar steatosis involving 30% of hepatocytes.
There was no evident sign of steatohepatitis and Perls’
staining was negative. Given the genotype 3 infection
and a very likely virally-induced steatosis, which is
not a risk factor of resistance to antiviral therapy
[3], a combined regimen with pegylated interferon-
a2a (180 lg QW) and ribavirin (800 mg QD) was ini-
tiated in December 2004. At week 4 of treatment, liver
tests were in normal range and HCV viral load had
decreased to 50,605 IU/ml but at week 12, HCV viral
load had relapsed to 150,567 IU/ml. Because of partial
response and good tolerance to treatment, ribavirin
dosage was increased to 1 g/d for the following 12
weeks. At week 24, viral load was still positive at
44,290 IU/ml and treatment was stopped. Three
months after stopping treatment, ALT and AST levels
were 1.4  N and normal, respectively, and viral load
was 84,355 IU/ml. Since metabolic steatosis is associ-
ated with non-response to antiviral therapy, insulin
resistance was assessed according to HOMA index,
which resulted to be 4.8 (4.07 mml/l  27 mU/22.5).
We concluded that the steatosis detected in this pa-
tient was metabolic rather than virally-induced, in
spite of the infection with HCV genotype 3. After
obtaining informed consent, treatment with pioglitaz-
one (Actos, Takeda Pharmaceuticals) was initiated
in November 2005 at the dosage of 45 mg per day.
During treatment, there was no side eﬀect, especially
no signiﬁcant weight gain. Transaminases and GGT
levels progressively normalized. Lipid parameters were
not signiﬁcantly modiﬁed. HOMA index decreased
from 4.8 to 3 and 1.3 after 3 and 5 months, respec-
tively. Then, after 5 months of pioglitazone pre-treat-
ment, a combination therapy with pegylated
interferon-a2a (180 lg QW) and ribavirin (1000 mg
QD) was added for a total duration of 48 weeks. At
this time, viral load was assessed by real time PCR
(Taqman Roche, lower limit of detection 15 IU/ml).
Starting with a level of 1,113,119 IU/ml prior to initi-
ating the second course of combination therapy, the
viral load decreased to 68,558 IU/ml after 4 weeks of
triple therapy. After 12 weeks, HCV RNA was unde-
tectable and remained negative until the end of treat-
ment. Pioglitazone and combinated antiviral therapy
were well tolerated without necessitating dose reduc-
tions or discontinuation. Treatment was stopped in
March 2007. Six months after the end of treatment,
transaminases were in normal range, HCV RNA was
still undetectable and HOMA index remained lower
than 2 (Fig. 1).
In this case report, improvement of insulin sensi-
tivity with pioglitazone was associated with sustained
virological response in a patient previously not
responding to pegylated interferon and ribavirin,
conﬁrming the possible role of insulin resistance in
the sensitivity to interferon [4]. Prior to initiating
the second course of antiviral therapy, a several
month-course of pioglitazone 45 mg/d was required
in order to signiﬁcantly reduce insulin resistance lev-
els, as assessed by the HOMA index, as previously
shown in patients with NASH [2]. In order to min-
imize potential bias, the same pegylated interferon
and the same dosages were used during the ﬁrst
and the second course of combination therapy with
similar adherence to treatment. Since we cannot ex-
clude that virological response during the second
course of combination therapy may be simply the
result of retreatment, randomized placebo controlled
trials are warranted before deﬁnitive conclusions
can be drawn. A multicenter trial assessing the eﬀect
of sequential administration of pioglitazone on the
response to antiviral therapy in naı¨ve HCV patients
with insulin resistance is currently being conducted
in France.
Fig. 1. Course of HCV RNA level during the ﬁrst course of peglyated
interferon a2a 180 lg QW + ribavirin 1000 mg QD (PegIFN+Riba)
(lower limit of detection 615 IU/ml) and during the second course of
PegIFN+Riba associated with pioglitazone 45 mg/d (lower limit of
detection 15 IU/ml). Course of homeostasis model assessment (HOMA)
index is indicated at the bottom of the ﬁgure.
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Correction of insulin resistance in chronic hepatitis C patients not
responding to the standard of care: More questions than answers
To the Editor:
We read with interest the comment by Serfaty and
collaborators on our previous paper, and congratulate
them for the successful outcome of this interesting case.
We fully agree that our approach may have been inade-
quate and concur that, based on this case report and on
other recent data [1–3], the pharmacological correction
of the level of insulin resistance prior to retreatment with
antivirals should be more aggressive, and possibly pre-
cede the administration of the interferon-alpha/ribavirin
combination, until a HOMA score associated with a
higher rate of sustained virological response has been
reached [4,5].
It is noteworthy that the patient described by Ser-
faty and colleagues was infected by the genotype 3a
of HCV. In in vitro models [6], the mechanism of
virally-associated insulin resistance has been reported
to be HCV genotype-speciﬁc, the genotype 3a being
partly associated with the downregulation of peroxi-
some proliferator-activated receptor (PPAR)-c. Treat-
ment of transfected cells with a PPAR-c agonist
(rosiglitazone) partially reverted the suppression of
the insulin signaling associated with the expression
of the HCV core protein [6]. Thus, it is possible
that the insulin sensitizing therapy should be tailored
according to the infecting HCV genotype. In the IN-
SPIRED-HCV trial, only one patient was infected
with genotype 3a. This patient had extensive ﬁbrosis
and a mild steatosis aﬀecting 20% of hepatocytes,
but no overweight or arterial hypertension. Quite
oddly, upon retreatment, her HOMA-IR score
underwent a surge from 2.65 to 11, while serum
HCV RNA level remained unmodiﬁed. We fear that
this paradoxical increase may have been the conse-
quence of a pharmacological interaction between
interferon-alpha and two additional drugs, i.e.
duloxetine and zopiclone, which have been occasion-
ally associated with glucose metabolism derange-
ments [6].
We remain convinced that correcting insulin resis-
tance is a rational option in chronic hepatitis C patients
failing to respond to combination therapy. However, the
modalities of this correction have to be fully explored.
The sequential administration of higher doses of insulin
sensitizers seems a reasonable approach, but the likely
genotype speciﬁcity of the mechanisms underlying the
insulin resistant state and the risk of pharmacological
interactions should both be taken in consideration be-
fore designing clinical trials. Finally, one should not for-
get that the most eﬀective way of correcting glucose
metabolism disturbances consists in lifestyle interven-
tions [7], such as diet modiﬁcations and increased phys-
ical activity, and that there is no excuse why chronic
hepatitis C patients should be spared such interventions.
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